647 related articles for article (PubMed ID: 10628899)
41. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
Martínez C; García-Martín E; Pizarro RM; García-Gamito FJ; Agúndez JA
Br J Cancer; 2002 Sep; 87(6):681-6. PubMed ID: 12237780
[TBL] [Abstract][Full Text] [Related]
42. Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme.
Tie Y; McPhail B; Hong H; Pearce BA; Schnackenberg LK; Ge W; Buzatu DA; Wilkes JG; Fuscoe JC; Tong W; Fowler BA; Beger RD; Demchuk E
Molecules; 2012 Mar; 17(3):3407-60. PubMed ID: 22421793
[TBL] [Abstract][Full Text] [Related]
43. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.
Reid JM; Kuffel MJ; Ruben SL; Morales JJ; Rinehart KL; Squillace DP; Ames MM
Clin Cancer Res; 2002 Sep; 8(9):2952-62. PubMed ID: 12231541
[TBL] [Abstract][Full Text] [Related]
44. Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers.
Rodríguez-Antona C; Jande M; Rane A; Ingelman-Sundberg M
Clin Pharmacol Ther; 2005 Apr; 77(4):259-70. PubMed ID: 15903124
[TBL] [Abstract][Full Text] [Related]
45. Estrogen regulation of the cytochrome P450 3A subfamily in humans.
Williams ET; Leyk M; Wrighton SA; Davies PJ; Loose DS; Shipley GL; Strobel HW
J Pharmacol Exp Ther; 2004 Nov; 311(2):728-35. PubMed ID: 15282264
[TBL] [Abstract][Full Text] [Related]
46. Bimodal distribution of renal cytochrome P450 3A activity in humans.
Haehner BD; Gorski JC; Vandenbranden M; Wrighton SA; Janardan SK; Watkins PB; Hall SD
Mol Pharmacol; 1996 Jul; 50(1):52-9. PubMed ID: 8700118
[TBL] [Abstract][Full Text] [Related]
47. Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem.
Yamamoto T; Kubota T; Ozeki T; Sawada M; Yokota S; Yamada Y; Kumagai Y; Iga T
Clin Chim Acta; 2005 Dec; 362(1-2):147-54. PubMed ID: 16024008
[TBL] [Abstract][Full Text] [Related]
48. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
[TBL] [Abstract][Full Text] [Related]
49. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines.
Chang TK; Yu L; Maurel P; Waxman DJ
Cancer Res; 1997 May; 57(10):1946-54. PubMed ID: 9157990
[TBL] [Abstract][Full Text] [Related]
50. Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4.
Hsu MH; Johnson EF
J Biol Chem; 2019 May; 294(20):8015-8022. PubMed ID: 30926609
[TBL] [Abstract][Full Text] [Related]
51. Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.
Ince I; Knibbe CA; Danhof M; de Wildt SN
Clin Pharmacokinet; 2013 May; 52(5):333-45. PubMed ID: 23463352
[TBL] [Abstract][Full Text] [Related]
52. CYP3A gene expression in human gut epithelium.
Kolars JC; Lown KS; Schmiedlin-Ren P; Ghosh M; Fang C; Wrighton SA; Merion RM; Watkins PB
Pharmacogenetics; 1994 Oct; 4(5):247-59. PubMed ID: 7894497
[TBL] [Abstract][Full Text] [Related]
53. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver.
Schuetz JD; Beach DL; Guzelian PS
Pharmacogenetics; 1994 Feb; 4(1):11-20. PubMed ID: 8004129
[TBL] [Abstract][Full Text] [Related]
54. Cytochrome P450 and anticancer drugs.
Fujita K
Curr Drug Metab; 2006 Jan; 7(1):23-37. PubMed ID: 16454691
[TBL] [Abstract][Full Text] [Related]
55. Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny.
Giebel NL; Shadley JD; McCarver DG; Dorko K; Gramignoli R; Strom SC; Yan K; Simpson PM; Hines RN
Drug Metab Dispos; 2016 Jul; 44(7):1027-37. PubMed ID: 26921389
[TBL] [Abstract][Full Text] [Related]
56. Differential expression of human cytochrome P450 enzymes from the CYP3A subfamily in the brains of alcoholic subjects and drug-free controls.
Booth Depaz IM; Toselli F; Wilce PA; Gillam EM
Drug Metab Dispos; 2013 Jun; 41(6):1187-94. PubMed ID: 23491640
[TBL] [Abstract][Full Text] [Related]
57. CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell lines.
Gervot L; Carrière V; Costet P; Cugnenc PH; Berger A; Beaune PH; de Waziers I
Environ Toxicol Pharmacol; 1996 Dec; 2(4):381-8. PubMed ID: 21781746
[TBL] [Abstract][Full Text] [Related]
58. Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation.
Niwa T; Yasumura M; Murayama N; Yamazaki H
Drug Metab Lett; 2014; 8(1):43-50. PubMed ID: 24484539
[TBL] [Abstract][Full Text] [Related]
59. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles.
Rodríguez-Antona C; Sayi JG; Gustafsson LL; Bertilsson L; Ingelman-Sundberg M
Biochem Biophys Res Commun; 2005 Dec; 338(1):299-305. PubMed ID: 16171783
[TBL] [Abstract][Full Text] [Related]
60. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR.
Nishimura M; Yaguti H; Yoshitsugu H; Naito S; Satoh T
Yakugaku Zasshi; 2003 May; 123(5):369-75. PubMed ID: 12772594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
